Clovis Oncology Inc. (CLVS)

32.64
NASDAQ : Health Technology
Prev Close 32.64
Day Low/High 0.00 / 0.00
52 Wk Low/High 31.19 / 86.26
Avg Volume 891.50K
Exchange NASDAQ
Shares Outstanding 52.65M
Market Cap 1.70B
EPS -7.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Interesting CLVS Put And Call Options For January 2021

Interesting CLVS Put And Call Options For January 2021

Investors in Clovis Oncology Inc saw new options become available this week, for the January 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Clovis Oncology To Present At The Morgan Stanley Global Healthcare Conference

Clovis Oncology To Present At The Morgan Stanley Global Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.

Relative Strength Alert For Clovis Oncology

Relative Strength Alert For Clovis Oncology

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Clovis Oncology Announces First Patient Enrolled In The Phase 3 ATHENA Trial

Clovis Oncology Announces First Patient Enrolled In The Phase 3 ATHENA Trial

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis' Rubraca ® (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers...

Clovis Oncology Announces Second Quarter 2018 Operating Results

Clovis Oncology Announces Second Quarter 2018 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2018, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the second half of 2018.

Buy These 3 Risky Biotech Stocks

Buy These 3 Risky Biotech Stocks

Is the pharma sector fever heating up in 2H18? Drug investors, get ready as there could be some good trades to be made.

Clovis Oncology To Announce Second Quarter 2018 Financial Results And Host Webcast Conference Call On August 1

Clovis Oncology To Announce Second Quarter 2018 Financial Results And Host Webcast Conference Call On August 1

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2018 financial results on Wednesday, August 1, 2018, after the close of the U.

Clovis Oncology Receives EMA Validation For Its Application For A New Indication For Rubraca®▼ (rucaparib) As Maintenance Treatment For Women With Recurrent Ovarian Cancer

Clovis Oncology Receives EMA Validation For Its Application For A New Indication For Rubraca®▼ (rucaparib) As Maintenance Treatment For Women With Recurrent Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Medicines Agency (EMA) has validated the application for a Type II variation to the marketing authorization for Rubraca ® (rucaparib) to include maintenance treatment of adult patients...

Clovis Oncology To Present At The Goldman Sachs 39th Annual Global Healthcare Conference 2018

Clovis Oncology To Present At The Goldman Sachs 39th Annual Global Healthcare Conference 2018

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Clovis Oncology Submits Application To EMA To Expand Use Of Rubraca®▼ (rucaparib) To Include Maintenance Treatment For Women With Recurrent Ovarian Cancer

Clovis Oncology Submits Application To EMA To Expand Use Of Rubraca®▼ (rucaparib) To Include Maintenance Treatment For Women With Recurrent Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the submission of a regulatory application to the European Medicines Agency (EMA), as part of a type II variation seeking to expand the marketing authorization for Rubraca (rucaparib) to include...

Groupon, Applied Materials, Adobe Systems: 'Mad Money' Lightning Round

Groupon, Applied Materials, Adobe Systems: 'Mad Money' Lightning Round

Jim Cramer weighs in on Groupon, Applied Materials, Adobe Systems, Cara Therapeutics, Watsco, CBRL Group, Pilgrim's Pride and more.

Get Used to Uncertainty: Cramer's 'Mad Money' Recap (Tuesday 5/29/18)

Get Used to Uncertainty: Cramer's 'Mad Money' Recap (Tuesday 5/29/18)

Global uncertainty, interest rates, and profit-taking are weighing on the markets. But Jim Cramer argues these events are good for the U.S.

Clovis Oncology Announces European Commission Authorization Of Rubraca® (rucaparib) For Women With Recurrent Ovarian Cancer

Clovis Oncology Announces European Commission Authorization Of Rubraca® (rucaparib) For Women With Recurrent Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic),...

Clovis Oncology Announces Presentations At 2018 ASCO Annual Meeting

Clovis Oncology Announces Presentations At 2018 ASCO Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that seven abstracts highlighting progress in the Rubraca preclinical research and clinical development program will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting...

4 Names to Buy in a Refreshed Biotech Space

4 Names to Buy in a Refreshed Biotech Space

After a strong week for the biotech sector, these names have potential catalysts to move shares.

CORRECTING And REPLACING Clovis Oncology To Present At The Bank Of America Merrill Lynch Healthcare Conference 2018

CORRECTING And REPLACING Clovis Oncology To Present At The Bank Of America Merrill Lynch Healthcare Conference 2018

Presentation and webcast time listed in first paragraph of release should read: Wednesday, May 16, 2018 at 11:20 AM local time (instead of Thursday, May 17, 2018 at 10:00 AM Pacific Time).

Clovis Oncology Announces First Quarter 2018 Operating Results

Clovis Oncology Announces First Quarter 2018 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2018, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for 2018.

Two Oncology Stocks I Like Now

Two Oncology Stocks I Like Now

M&A activity should pick up in the biotech space.

Clovis Oncology To Announce First Quarter 2018 Financial Results And Host Webcast Conference Call On May 8

Clovis Oncology To Announce First Quarter 2018 Financial Results And Host Webcast Conference Call On May 8

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2018 financial results on Tuesday, May 8, 2018, after the close of the U.

Some Biotech Stocks to Add Exposure To

Some Biotech Stocks to Add Exposure To

Secondary offerings create buying opportunities.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Infographic: Understanding Ovarian Cancer (Graphic: Business Wire)

Infographic: Understanding Ovarian Cancer (Graphic: Business Wire)

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GSM, RSPP, SVM, TDS Downgrades: AG, BGS, DJCO, EVC, GLRE, TCP Initiations: CLVS Read on to get TheStreet Quant Ratings' detailed report:

Clovis Oncology Initiates Early Access Program For Rucaparib As Treatment And As Maintenance Therapy In Recurrent Ovarian Cancer In Europe

Clovis Oncology Initiates Early Access Program For Rucaparib As Treatment And As Maintenance Therapy In Recurrent Ovarian Cancer In Europe

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer.

CHMP Grants Positive Opinion For Clovis Oncology's Rubraca® (rucaparib) Tablets

CHMP Grants Positive Opinion For Clovis Oncology's Rubraca® (rucaparib) Tablets

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the...

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Clovis Oncology Announces Notice Of Allowance For Rucaparib High Dosage Strength Tablet Patent With Expiration In 2035

Clovis Oncology Announces Notice Of Allowance For Rucaparib High Dosage Strength Tablet Patent With Expiration In 2035

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office in United States Patent Application 14/828,065 with claims...

TheStreet Quant Rating: D- (Sell)